0 9 Apoptosis Apoptosis NNP 10 18 mediated mediate VBN 19 21 by by IN 22 25 HIV HIV NNP 26 34 protease protease NN 35 37 is be VBZ 38 46 preceded precede VBN 47 49 by by IN 50 58 cleavage cleavage NN 59 61 of of IN 62 67 Bcl-2 bcl-2 NN 67 68 . . . 70 80 Expression expression NN 81 83 of of IN 84 87 the the DT 88 93 human human JJ 94 110 immunodeficiency immunodeficiency NN 111 116 virus virus NN 117 121 type type NN 122 123 1 1 CD 124 125 ( ( ( 125 128 HIV HIV NNP 128 129 ) ) ) 130 138 protease protease NN 139 141 in in IN 142 150 cultured culture VBN 151 156 cells cell NNS 157 162 leads lead VBZ 163 165 to to TO 166 175 apoptosis apoptosis NN 175 176 , , , 177 185 preceded precede VBN 186 188 by by IN 189 197 cleavage cleavage NN 198 200 of of IN 201 206 bcl-2 bcl-2 NN 206 207 , , , 208 209 a a DT 210 213 key key JJ 214 222 negative negative JJ 223 232 regulator regulator NN 233 235 of of IN 236 240 cell cell NN 241 246 death death NN 246 247 . . . 248 250 In in IN 251 259 contrast contrast NN 259 260 , , , 261 262 a a DT 263 267 high high JJ 268 273 level level NN 274 276 of of IN 277 282 bcl-2 bcl-2 NN 283 291 protects protect VBZ 292 297 cells cell NNS 298 300 in in FW 301 306 vitro vitro FW 307 310 and and CC 311 313 in in FW 314 318 vivo vivo FW 319 323 from from IN 324 327 the the DT 328 333 viral viral JJ 334 342 protease protease NN 343 346 and and CC 347 355 prevents prevent VBZ 356 360 cell cell NN 361 366 death death NN 367 376 following follow VBG 377 380 HIV HIV NNP 381 390 infection infection NN 391 393 of of IN 394 399 human human JJ 400 411 lymphocytes lymphocyte NNS 411 412 , , , 413 418 while while IN 419 427 reducing reduce VBG 428 431 the the DT 432 438 yields yield NNS 439 441 of of IN 442 447 viral viral JJ 448 458 structural structural JJ 459 467 proteins protein NNS 467 468 , , , 469 480 infectivity infectivity NN 480 481 , , , 482 485 and and CC 486 491 tumor tumor NN 492 500 necrosis necrosis NN 501 507 factor factor NN 508 513 alpha alpha NN 513 514 . . . 515 517 We we PRP 518 525 present present VBP 526 527 a a DT 528 533 model model NN 534 537 for for IN 538 541 HIV HIV NNP 542 553 replication replication NN 554 556 in in IN 557 562 which which WDT 563 566 the the DT 567 572 viral viral JJ 573 581 protease protease NN 582 590 depletes deplete VBZ 591 594 the the DT 595 603 infected infected JJ 604 609 cells cell NNS 610 612 of of IN 613 618 bcl-2 bcl-2 NN 618 619 , , , 620 627 leading lead VBG 628 630 to to TO 631 640 oxidative oxidative JJ 641 657 stress-dependent stress-dependent JJ 658 668 activation activation NN 669 671 of of IN 672 674 NF NF NNP 675 680 kappa kappa NN 681 682 B B NNP 682 683 , , , 684 685 a a DT 686 694 cellular cellular JJ 695 701 factor factor NN 702 710 required require VBN 711 714 for for IN 715 718 HIV HIV NNP 719 732 transcription transcription NN 732 733 , , , 734 737 and and CC 738 748 ultimately ultimately RB 749 751 to to TO 752 756 cell cell NN 757 762 death death NN 762 763 . . . 764 772 Purified purify VBN 773 778 bcl-2 bcl-2 NN 779 781 is be VBZ 782 789 cleaved cleave VBN 790 792 by by IN 793 796 HIV HIV NNP 797 805 protease protease NN 806 813 between between IN 814 827 phenylalanine phenylalanine NN 828 831 112 112 CD 832 835 and and CC 836 843 alanine alanine NN 844 847 113 113 CD 847 848 . . . 849 852 The the DT 853 860 results result NNS 861 868 suggest suggest VBP 869 870 a a DT 871 874 new new JJ 875 881 option option NN 882 885 for for IN 886 889 HIV HIV NNP 890 894 gene gene NN 895 902 therapy therapy NN 902 903 ; ; : 904 909 bcl-2 bcl-2 NN 910 917 muteins mutein NNS 918 922 that that WDT 923 927 have have VBP 928 940 noncleavable noncleavable JJ 941 952 alterations alteration NNS 953 964 surrounding surround VBG 965 968 the the DT 969 972 HIV HIV NNP 973 981 protease protease NN 982 990 cleavage cleavage NN 991 995 site site NN 995 996 . . .